ResearchA randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)
ResearchInternational experts consensus on optimal central vascular access device selection and management for patients with cancer
ResearchReal-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States
ResearchBaseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry
ResearchHealth-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK+ non-small cell lung cancer (ALTA-1L)
ResearchMulti-omic molecular profiling guide's efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial
ResearchResource-Stratified Guideline-Based Cancer Care Should Be a Priority: Historical Context and Examples of Success
ResearchEconomic burden in patients with ALK+ non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors
ResearchInternational Perspective on the Pursuit of Quality in Cancer Care: Global Application of QOPI and QOPI Certification
ResearchReal-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung Cancer
ResearchImproving Quality of Cancer Care by Participating in Quality Oncology Practice Initiative Certification Program
ResearchResponse to Abemaciclib After 10 Lines of Therapy Including Palbociclib in Metastatic Breast Cancer: A Case Report With Literature Review
ResearchSafety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial
ResearchRemarkable Role of Chemotherapy in Selected ALK-Positive Non-Small-Cell Lung Cancer Before or After Targeted Therapy: Two Case Reports
ResearchImmunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non-Small-Cell Lung Cancer